Transcription factors as therapeutic targets in chronic kidney disease

Akihito Hishikawa, Kaori Hayashi, Hiroshi Itoh

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation.

Original languageEnglish
Article number1123
JournalMolecules
Volume23
Issue number5
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

kidney diseases
Chronic Renal Insufficiency
Transcription Factors
Epigenomics
NF-E2 Transcription Factor
Clinical Trials
Kidney
Therapeutics
Podocytes
Excipients
Kidney Diseases
Transcription factors
Deregulation
Pharmaceutical Preparations
Anemia
Chemical activation
drugs
Modulation
anemias
GKLF protein

Keywords

  • Bardoxolone methyl
  • Chronic kidney disease (CKD)
  • HIF
  • KLF4
  • Nrf2
  • Renin–angiotensin system (RAS)

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Transcription factors as therapeutic targets in chronic kidney disease. / Hishikawa, Akihito; Hayashi, Kaori; Itoh, Hiroshi.

In: Molecules, Vol. 23, No. 5, 1123, 01.01.2018.

Research output: Contribution to journalReview article

@article{6c6d9b6af7df4ece8f10ed8526dcce3c,
title = "Transcription factors as therapeutic targets in chronic kidney disease",
abstract = "The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation.",
keywords = "Bardoxolone methyl, Chronic kidney disease (CKD), HIF, KLF4, Nrf2, Renin–angiotensin system (RAS)",
author = "Akihito Hishikawa and Kaori Hayashi and Hiroshi Itoh",
year = "2018",
month = "1",
day = "1",
doi = "10.3390/molecules23051123",
language = "English",
volume = "23",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Transcription factors as therapeutic targets in chronic kidney disease

AU - Hishikawa, Akihito

AU - Hayashi, Kaori

AU - Itoh, Hiroshi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation.

AB - The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation.

KW - Bardoxolone methyl

KW - Chronic kidney disease (CKD)

KW - HIF

KW - KLF4

KW - Nrf2

KW - Renin–angiotensin system (RAS)

UR - http://www.scopus.com/inward/record.url?scp=85047191077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047191077&partnerID=8YFLogxK

U2 - 10.3390/molecules23051123

DO - 10.3390/molecules23051123

M3 - Review article

C2 - 29747407

AN - SCOPUS:85047191077

VL - 23

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 5

M1 - 1123

ER -